Clinical Trial

A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

Name: A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients — clinical trial record (NCT07722767)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A Phase 1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously (IV) administered CLN-049 in combination with azacitidine (Aza) and venetoclax (Ven) in patients with newly diagnosed (ND) AML.

Trial Details

NCT Number	NCT07722767
Lead Sponsor	Cullinan Therapeutics Inc.
Conditions	AML (Acute Myeloid Leukemia)
Enrollment	90 participants
Start Date	2026-10-15
Primary Completion	2027-09-30 (estimated)
Study Completion	2030-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-23